Skip to main content
SpringerLink
Log in

Sensitivity of monoclonal antibodies to carcinoembryonic antigen, tissue polypeptide antigen, alpha-fetoprotein, carbohydrate antigen 50, and carbohydrate antigen 19-9 in the diagnosis of colorectal adenocarcinoma

  • Original Contributions
  • Published:
Diseases of the Colon & Rectum

Abstract

PURPOSE: This study was designed to establish the sensitivity of monoclonal antibodies to carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), tissue polypeptide antigen (TPA), carbohydrate antigen 50 (CA 50), and carbohydrate antigen 19-9 (CA 19-9) and the efficacy of the joint determination of several tumor markers, as well as the dynamics of postoperative normalization of each marker in the absence of recurrence. MATERIALS AND METHODS: A prospective study was carried out in 100 patients subjected to surgical resection of colon adenocarcinoma. Serum concentrations of these markers were determined the day before surgery and seven days, two months, and six months after surgery. RESULTS: The results demonstrate that sensitivity increased as the disease spread and that CA 19-9 was the most sensitive tumor marker. The rate of false negatives was 40 percent for Dukes Stage A lesions, 19 percent for Dukes Stage B, 7 percent for Dukes Stage C, and 0 percent for Dukes Stage D. Determination of two markers (CA 19-9 and CEA) provided the greatest sensitivity in Stages A and D tumors (60 percent and 100 percent, respectively); the incidence did not change when measurements of other antigens were associated. For Stages B and C, determination of at least three markers was necessary, the association of CEA, TPA, and CA 19-9 being that which showed the greatest sensitivity, 78 percent and 91 percent, respectively. CONCLUSIONS: It would be advisable to include monoclonal antibody determination of CEA, TPA, and CA 19-9 in the diagnosis of adenocarcinoma, despite the fact that ultimate sensitivity will depend on the degree of tumor extension or on the presence of metastasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Chapter © 2017

References

  1. Parkin DM, Stjernsward J, Muir CS. Estimated world incidence of twelve important cancers. Bull World Health Organ 1984;62:389–410.

    PubMed  Google Scholar 

  2. Muir C, Waterhouse J, Mack T, Powel J. Cancer incidence in five continents, Vol. 5. Lyon: IARC Scientific Publication, 1987:88–96.

    Google Scholar 

  3. Haenszel W, Correa P, eds. Epidemiology of cancer of the digestive tract. La Haya: Martinus Nijhoff Publishers, 1982:84–126.

    Google Scholar 

  4. Kune S, Kune GA, Watson L. The Melbourne Colorectal study: incidence findings by age, sex, site, migrants and religion. Int J Epidemiol 1986;15:483–93.

    PubMed  Google Scholar 

  5. Lynch PM, Lynch HT, eds. Colon cancer genetics. New York: Van Nostrand Reinhold, 1985.

    Google Scholar 

  6. Levin KE, Dozois RR. Epidemiology of large bowel cancer. World J Surg 1991;15:562–7.

    Article  PubMed  Google Scholar 

  7. Boring CC, Squires TS, Tong T. Cancer statistics. Bol Asoc Med P R 1991;83:225–42.

    PubMed  Google Scholar 

  8. Bolin S, Franzen L, Nilsson E, Sjodhal R. Carcinoma of the colon and rectum: tumors missed by radiologic examination in 61 patients. Cancer 1988;61:1999–2008.

    PubMed  Google Scholar 

  9. Beynon J, Foy DM, Roe AM, Temple LN, Mortensen ND. Endoluminal ultrasound in the assessment of local invasion of rectal cancer. Br J Surg 1986;73:474–7.

    PubMed  Google Scholar 

  10. Saitoh N, Okui K, Sarashina H, Suzuki M, Arai T, Nunomura M. Evaluation of echographic diagnosis of rectal cancer using intrarectal ultrasonic examination. Dis Colon Rectum 1986;29:234–42.

    PubMed  Google Scholar 

  11. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495–7.

    Article  PubMed  Google Scholar 

  12. Delaloye B, Bischof-Delaloye A, Bucheggerm F,et al. Detection of colorectal carcinoma by emission computerized tomography after injection of I123 labeled Fab or F(ab′)2 fragments from monoclonal anticarcinoembryonic antigen antibodies. J Clin Invest 1986;77:301–11.

    PubMed  Google Scholar 

  13. Hyams DM, Esteban JM, Lollo CP, Beatty BG, BeattyJD. Therapy of peritoneal carcinomatosis of human colon cancer xenografts with yttrium 90-labeled anticarcinoembryonic antigen antibody 2CEO25. Arch Surg 1987;122:1333–7.

    PubMed  Google Scholar 

  14. Cohn KH, Welt S, Banner WP,et l. Localization of radioiodinated monoclonal antibody in colorectal cancer. Arch Surg 1987;122:1425–9.

    PubMed  Google Scholar 

  15. Deland FH, Kim EE, Primus FJ, Dine ME, Goldenberg DM.In vivo radioimmunodetection of occult recurrent colonic carcinoma. AJR 1982;138:145–8.

    PubMed  Google Scholar 

  16. Johnston WW. Applications of monoclonal antibodies in clinical cytology as exemplified by studies with monoclonal antibody B72.3. Acta Cytol 1987;31:535–56.

    Google Scholar 

  17. Carrasquillo JA, Sugarbaker P, Colcher D,et al. Peritoneal carcinomatosis: imaging with intraperitoneal injection of I131-labeled B.72.3 monoclonal antibody. Radiology 1988;167:35–40.

    PubMed  Google Scholar 

  18. Johnston VG, Scholm J, Paterson AJ, Bennett AJ, Magnani JL, Colcher D. Analysis of a human tumor associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res 1986;46:850–7.

    PubMed  Google Scholar 

  19. Johnston WW, Szpak CA, Lottich SC, Thor A, Scholm J. Use of a monoclonal antibody (B72.3) as a novel immunocytochemical adjunct for the diagnosis of carcinoma in fine needle aspiration biopsy specimens. Hum Pathol 1986;17:501–13.

    PubMed  Google Scholar 

  20. Takahashi T, Yamaguchi T, Kitamura K,et al. Clinical application of a monoclonal antibody: drug conjugates for immunotargeting chemotherapy of colorectal carcinoma. Cancer 1988;61:881–8.

    PubMed  Google Scholar 

  21. Mitchell E, Schlom J. Monoclonal antibodies in gastrointestinal cancers. Semin Oncol 1988;15:170–80.

    PubMed  Google Scholar 

  22. Lamiquiz A, Dommguez MJ, Lazaro S,et al. Interés clínico del CEA monoclonal y del Ca. 19.9 en el diagnóstico y seguimiento del cancer gastrointestinal: resultados preliminares. Cir Esp 1988;48:372–8.

    Google Scholar 

  23. Szymendera JJ, Marek DS, Nowacki P, Szalowski AW, Kaminska JA. Predictive value of plasma CEA levels: preoperative prognosis and postoperative monitoring of patients with colorectal carcinoma. Dis Colon Rectum 1982;25:46–52.

    PubMed  Google Scholar 

  24. Miridi G, Amanti C, Consorti F,et al. Usefulness of preoperative CEA levels in the assessment of the colorectal cancer patient. J Surg Oncol 1983;22:257–60.

    PubMed  Google Scholar 

  25. Wolmark N, Fisher B, Wieand HS,et al. The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer: results from NSABP clinical trials. Ann Surg 1984;199:375–81.

    PubMed  Google Scholar 

  26. Kohler JP, Simonitz D, Paloyan D. Preoperative CEA level: a prognostic test in patients with colorectal car cinoma. Am Surg 1980;46:449–52.

    PubMed  Google Scholar 

  27. Herrera MA, Chu TM, Holyoke ED. Carcinoembryonic antigen (CEA) as prognosis and monitoring test in clinically complete resection of colorectal carcinoma. Ann Surg 1976;183:5–9.

    PubMed  Google Scholar 

  28. Steele G, Ellemberg S, Ramming K,et al. CEA monitoring among patients in multi-institutional adjuvant GI therapy protocols. Ann Surg 1982;196:162–9.

    PubMed  Google Scholar 

  29. Imperato JP, Sener SF, Chiniel J,et al. Colorectal cancer in Illinois: demographics, treatment results and prognostic indicators in 7791 patients treated between 1976–1978. Proc. ASCO 1988;7:353–7.

    Google Scholar 

  30. Staab HJ, Brümmendorf T, Hornung A, Anderer FA, Kieninger G. The clinical validity of circulating tumor associated antigens CEA and Ca.19-9 in primary diagnosis and follow-up of patients with gastrointestinal malignancies. Klin Wochens Schr 1985;63:106–115.

    Article  Google Scholar 

  31. Oehr P, Derigs G, Altmann R. Evaluation and characterization of tumor-associated antigens by conversion of inverse distribution function values into specificity sensitivity diagrams. Tumor-Diagnostik 1981;2:283–90.

    Google Scholar 

  32. Lüthgens M, Schlegen G. Combined use of carcinoembryonic antigen and tissue polypeptide antigen in oncology therapy and surveillance. Cancer Detect Prev 1983;6:51–9.

    PubMed  Google Scholar 

  33. Baumann M, Brand K, Giedl J,et al. Significance of serum phosphohexose isomerase in gastrointestinal cancer at different stages. Oncology 1988;45:153–8.

    PubMed  Google Scholar 

  34. Putzki H, Student A, Jablonski M, Heymann H. Comparison of the tumor markers CEA, TPA and Ca. 19-9 in colorectal carcinoma. Cancer 1987;59:223–6.

    PubMed  Google Scholar 

  35. Kuusela P, Jalanko P, Roberts P,et al. Comparison of Ca.19.9 and carcinoembryonic antigen (CEA) in the serum of patients with colorectal diseases. Br J Cancer 1984;49:135–9.

    PubMed  Google Scholar 

  36. Herlyn M, Jhen JW, Sears HF,et al. Detection of a circulating gastrointestinal cancer antigen in sera of patients with gastrointestinal malignances by a double determination immunoassay with monoclonal antibodies against human blood group determinants. Clin Exp Immunol 1984;55:23–35.

    PubMed  Google Scholar 

  37. Ritts RE Jr, Del Villano BC, Go VL, Heberman RB, Klug TL, Zurawski VR. Initial clinical evaluation of an immunoradiometric assay for Ca.19-9 using the NCI serum bank. Int J Cancer 1984;33:339–45.

    PubMed  Google Scholar 

  38. Genollá G, Moragas M, Encabo G, Buxeda M, Cuartero A, Sorribes A. Valor de la determinación sérica del antígeno Ca.50 en las neoplasias de colon. Rev Esp Med Nuclear 1988;6:197–206.

    Google Scholar 

  39. Holmgren J, Lindholm L, Persson B,et al. Detection by monoclonal antibody of carbohydrate antigen Ca.50 in patients with carcinoma. BMJ 1984;288:1479–82.

    PubMed  Google Scholar 

  40. Lamiquiz A, Loizate A, Domínguez MJ. Elevación preoperatoria de CEA, CA.19.9 and CA.50 en los estadíos irresecables del cáncer colorrectal. Rev Esp Enferm Dig 1988;73:323–4.

    Google Scholar 

  41. Bruhn HD, Everding A, Joos B, Hedderich J. Clinical experience with the carbohydrate antigen Ca.50 in the serum of carcinoma patients. In: Holgrem J, ed. Tumor marker antigens. Lund: Studentlitteratur, 1985:92–103.

    Google Scholar 

  42. Jalanko H, McGlund C, Roberts PJ, Kuusela P. Tumor markers in gastrointestinal cancer. In: Holgrem J, ed. Tumor marker antigens. Lund: Studentlitteratur, 1985:112–21.

    Google Scholar 

  43. Ruibal A, Encabo G, Gefaell R, Martinez-Miralles E, Fort JM. Clinical interest of serum CA 19-9 determination in differential diagnosis of patients with peptic ulcers and gastric cancer. Bull Cancer (Paris) 1983;70:438–40.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service of General Surgery and Digestives Diseases, Hospital Universitario de Getafe, Madrid, Spain

    J. A. Alvarez M.D., J. Marín M.D., J. M. Jover M.D., R. Fernández M.D., J. Fradejas M.D. & M. Moreno M.D.

Authors
  1. J. A. Alvarez M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Marín M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. M. Jover M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Fernández M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Fradejas M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Moreno M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Alvarez, J.A., Marín, J., Jover, J.M. et al. Sensitivity of monoclonal antibodies to carcinoembryonic antigen, tissue polypeptide antigen, alpha-fetoprotein, carbohydrate antigen 50, and carbohydrate antigen 19-9 in the diagnosis of colorectal adenocarcinoma. Dis Colon Rectum 38, 535–542 (1995). https://doi.org/10.1007/BF02148856

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02148856

Key words

Search

Navigation